Qingyu Luo is a research fellow in Dr. Andrew Lane’s lab at the Dana-Farber Cancer Institute and a research fellow at Harvard Medical School. He is focusing on the application of cutting-edge technology such as functional genomics to discover cures for blood cancer. In his PhD research, he studied how the tumor suppressor ARID1A prevents esophageal cancer. He also defined novel molecular mechanisms that protect ovarian cancer cells from dying in the setting of chemotherapy. He has 9 first-author publications in high-impact journals (average impact factor > 10). Now, Qingyu is applying his cancer biology expertise to high-risk blood cancers including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). His goal is to reveal how BPDCN functions to identify novel therapies that lead to cures of this malignancy, and to find parallels of BPDCN biology in other blood cancers that can also be exploited therapeutically.